

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No.	V9661.0078
		First Inventor	Joseph Peiris
		Title	DIAGNOSTIC ASSAY FOR THE HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
		Express Mail Label No.	EV 988 622 510 US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) 2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. 3. <input checked="" type="checkbox"/> Specification [Total Pages 86] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 94] 5. Oath or Declaration [Total Sheets 2] a. <input checked="" type="checkbox"/> Unexecuted b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		7. <input checked="" type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Copy 1 and Copy 2) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input checked="" type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> Paper c. <input checked="" type="checkbox"/> Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of (when there is an assignee) Attorney 11. <input type="checkbox"/> English Translation Document (if applicable) 12. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations 13. <input type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input type="checkbox"/> Other:	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Prior application information: Examiner _____

Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number: **32172** ☒ Correspondence address below

Name	DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP Charles E. Miller				
Address	1177 Avenue of the Americas 41st Floor				
City	New York	State	NY	Zip Code	10036-2714
Country	US	Telephone	(212) 835-1400	Fax	(212) 997-9880

Name (Print/Type)	Hua Gao	Registration No. (Attorney/Agent)	40,414
Signature	<i>Hua Gao (Reg. No. 40,414)</i>	Date	March 24, 2004

for: Charles E. Miller (24,576)

15992 U.S. PTO
032404

FEE TRANSMITTAL for FY 2004		Complete if Known	
Effective 10/01/2003, Patent fees are subject to annual revision.		Application Number	Not Yet Assigned
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	Concurrently Herewith
TOTAL AMOUNT OF PAYMENT (\$)		First Named Inventor	Joseph Peiris
781.00		Examiner Name	Not Yet Assigned
		Art Unit	N/A
		Attorney Docket No.	V9661.0078

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input type="checkbox"/> Check	<input checked="" type="checkbox"/> Credit Card	3. ADDITIONAL FEES	
<input type="checkbox"/> Money Order	<input type="checkbox"/> Other		
<input type="checkbox"/> None			
Deposit Account: 50-2215			
Deposit Account Name: Dickstein Shapiro Morin & Oshinsky LLP			
The Director is authorized to: (check all that apply)			
<input type="checkbox"/> Charge fee(s) indicated below			
<input checked="" type="checkbox"/> Credit any overpayments			
<input type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s)			
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.			

FEE CALCULATION	
1. BASIC FILING FEE	
Large Entity	Small Entity
Fee Code (\$)	Fee Code (\$)
1001 770	2001 385
1002 340	2002 170
1003 530	2003 265
1004 770	2004 385
1005 160	2005 80
SUBTOTAL (1) (\$) 385.00	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	
Total Claims	21
Independent Claims	12
Multiple Dependent	
SUBTOTAL (2) (\$) 396.00	

FEE CALCULATION	
Large Entity	Small Entity
Fee Code (\$)	Fee Code (\$)
1202 18	2202 9
1201 86	2201 43
1203 290	2203 145
1204 86	2204 43
1205 18	2205 9
SUBTOTAL (3) (\$) 0.00	

SUBMITTED BY		(Complete if applicable)	
Name (Print/Type)	Hua Gao	Registration No. (Attorney/Agent)	40,414
Signature	<i>[Signature]</i>	Telephone	(212) 835-1430
		Date	March 24, 2004

for: Charles E. Miller (24,576)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 988 622 510 US in an envelope addressed to:

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on March 24, 2004
Date



Signature

Izumi Yokoyama, Ph.D.

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Specification (86 pages)
Drawings (18 figures, 94 sheets)
Oath or Declaration (2 page unsigned)
Specification Sequence Listing on CD-R (Copy 1 and Copy 2)
Statements verifying identity of above copies (1 page)
Utility Patent Application Transmittal (1 page)
Fee Transmittal (1 page)
Payment by credit card. Form PTO-2038 is attached (1 page)
Charge \$781.00 to credit card

TABLE OF CONTENTS
Attorney Docket No. V9661.0078

	Page
1. FIELD OF THE INVENTION	1
2. BACKGROUND	1
3. SUMMARY OF THE INVENTION	2
3.1. Definitions	5
4. DESCRIPTIONS OF THE FIGURES	12
5. DETAILED DESCRIPTION OF THE INVENTION	14
5.1. Nucleic Acid Sequences of hSARS Viruses	20
5.2. hSARS Viruses	24
5.2.1. Natural variants of hSARS viruses	24
5.2.2. Recombinant and chimeric hSARS viruses	26
5.3. Vaccines and Antivirals	31
5.3.1. Attenuation of hSARS viruses and variants Thereof	31
5.3.2. Formulation of vaccines	37
5.3.3. Adjuvants and carriers molecules	40
5.4. Preparation of Antibodies	42
5.5. Pharmaceutical Compositions and Kits	49
5.6. Detection Assays	53
5.7. Screening Assays	57
6. EXAMPLES	58
6.1. Clinical Subjects	58
6.2. Cell Line	59
6.3. Viral Infection	59
6.4. Virus Morphology	60
6.5. Antibody Response	60
6.6. Sequences of the hSARS Virus	61
6.7. Detection of the hSARS Virus in Nasopharyngeal Aspirates	63
6.7.1. RT-PCR Assay	63
6.8. A Quantitative TaqMan [®] Assay For hSARS Virus Detection	74
6.8.1. Materials and Methods	74
6.8.2. Results	75
6.8.3. Discussion	76
6.9. Clinical observations and Discussion	77
7. DEPOSIT	81
8. MARKET POTENTIAL	81
9. EQUIVALENTS	81
ABSTRACT	86